GLP-1 medicines
Start with your medicine. Each one has its own doses, rules and side effect advice, even when the active ingredient is shared.
Mounjaro
tirzepatideLicensed in the UK for weight management and type 2 diabetes. Doses, side effects, NHS access and switching.
36 guides Weekly injectionWegovy injection
semaglutideThe weekly semaglutide pen. Dose steps from 0.25 mg, heart evidence, storage and missed doses.
38 guides Daily tabletWegovy pill
oral semaglutideThe daily semaglutide tablet. How to take it on an empty stomach and how it differs from the pen.
20 guides Daily tabletFoundayo
orforglipronThe daily non-peptide tablet with no fasting rules. UK licence, doses and precautions.
20 guidesOther medicines and the pipeline
Ozempic in the UK: what it treats and how it works
Ozempic's UK licence for type 2 diabetes explained, with how weekly semaglutide works and how Ozempic differs from Wegovy for weight management.
3 min readOther medicinesOzempic doses: the UK starting and increase schedule
How Ozempic starts and increases in the UK, what pen strengths mean, what to do about missed doses and why GLP-1 milligrams do not convert between medicines.
3 min readOther medicinesOzempic safety: side effects, eye symptoms and warning signs
How to tell expected Ozempic stomach side effects from symptoms needing urgent help, including the updated UK eye safety advice on NAION.
3 min readOther medicinesRybelsus: oral semaglutide for type 2 diabetes
What Rybelsus is licensed for in the UK, how oral semaglutide works and how Rybelsus differs from Wegovy tablets for weight management.
3 min readOther medicinesHow to take Rybelsus: fasting, water and other tablets
How to take Rybelsus: fast for at least eight hours, swallow with up to 120 ml of water, wait 30 minutes, and skip a missed tablet.
3 min readOther medicinesRybelsus strengths: 3, 7 and 14 mg now 1.5, 4 and 9 mg
Why Rybelsus 3, 7 and 14 mg tablets became 1.5, 4 and 9 mg, how the strengths match, and why the table does not apply to Wegovy tablets.
3 min readOther medicinesSaxenda in the UK: liraglutide, eligibility and NHS access
Saxenda (liraglutide) is a daily weight-management injection. See who the UK licence covers and why NICE TA664 limits NHS access further.
3 min readOther medicinesUsing a daily Saxenda injection: dose steps and reviews
How to use Saxenda daily: 0.6 mg steps up to 3 mg, injection technique, missed doses, sharps and the adult 5% check after 12 weeks.
3 min readOther medicinesVictoza (liraglutide): diabetes use and UK discontinuation
Victoza is a liraglutide brand for type 2 diabetes. The brand was discontinued in the UK in December 2024 and other liraglutide pens remain.
3 min readOther medicinesTrulicity (dulaglutide) for type 2 diabetes
Trulicity is a weekly dulaglutide injection for type 2 diabetes. See how doses work, what reviews check and how it differs from weight-loss brands.
3 min readOther medicinesByetta: short-acting exenatide for type 2 diabetes
Byetta is a twice-daily exenatide injection for type 2 diabetes, timed around meals. Weekly exenatide is a different product and the two do not swap.
3 min readOther medicinesBydureon: prolonged-release exenatide explained
How weekly Bydureon differs from short-acting Byetta, why its release system sets the schedule and what to check when treatment changes.
3 min readOther medicinesLixisenatide: Lyxumia and insulin combination pens
What lixisenatide does in type 2 diabetes and why a GLP-1-only Lyxumia pen differs from a fixed combination pen that also contains insulin.
3 min readOther medicinesZepbound vs Mounjaro: same tirzepatide, different labels
Why US Zepbound information differs from UK Mounjaro guidance, including the US obesity and obstructive sleep apnoea indications.
3 min readOther medicinesRetatrutide: triple agonist research status in 2026
Retatrutide's three receptor targets, its phase 3 results and planned US filing, and why online research products are not approved medicines.
3 min readOther medicinesCagriSema: semaglutide plus cagrilintide research
What CagriSema contains, how amylin differs from GLP-1 and how to read the REDEFINE and REIMAGINE trial results while it stays investigational.
3 min readOther medicinesSurvodutide: GLP-1 and glucagon research explained
Survodutide's dual glucagon and GLP-1 action, its obesity and liver disease trials, and how 2026 phase 3 results differ from an approval.
3 min readOther medicinesAmycretin, now zenagamtide: what the research shows
The amycretin and zenagamtide names explained, with its GLP-1 and amylin receptor action, oral and injected trials, and its current research status.
3 min read